Logos Capital Overview
- Investor Type
- Hedge Fund
- Status
- Active
- Professionals
- 4
- Investments
- 88
- Portfolio
- 45
- Exits
- 44
Logos Capital General Information
Description
Founded in 2019, Logos Capital is a public and private investment fund based in San Francisco, California. The firm seeks to invest in life science and biotechnology companies.
Contact Information
Website
www.logoscapital.com
Year Founded
2019
Investor Status
Actively Seeking New Investments
Primary Investor Type
Hedge Fund
Other Investor Types
Venture Capital
Primary Office
- 1 Letterman Drive
- Building D, Suite D3-700
- San Francisco, CA 94129
- United States
+1 (415) 000-0000
Logos Capital Investments (88)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Synthego | 17-Feb-2022 | Later Stage VC | 00000 | Biotechnology | Generating Revenue | |
| 00000 00000000000 | 15-Feb-2022 | 00000 00000 | 000.00 | Other Healthcare Technology Systems | Generating Revenue | |
| 00000000 | 27-Jan-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| 0000000 0000000000 | 19-Jan-2022 | 00000 00000 | 000.00 | Drug Discovery | Startup | |
| 000000 000 | 17-Dec-2021 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | |
| 00000000 | 07-Dec-2021 | 00000 00000 | 00000 | Laboratory Services (Healthcare) | Clinical Trials - General | |
| 0000000 0000000000 | 07-Dec-2021 | 00000 00000 | 00000 | Drug Discovery | Product Development | |
| 00000 000000000000 | 09-Nov-2021 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
| Quanta Therapeutics | 26-Oct-2021 | Later Stage VC | 0000 | Biotechnology | Pre-Clinical Trials | 000000 00000000 00.0 |
| Cedilla Therapeutics | 25-Oct-2021 | Early Stage VC | 000.00 | Biotechnology | Generating Revenue |
Logos Capital Exits (44)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Vigil Neuro | 07-Jan-2022 | IPO | 0000 |
| 0000000 | 01-Nov-2021 | 000 | 00000 |
| 000000 00000000000 | 21-Oct-2021 | 000 | 00000 |
| 00000 00000000 | 08-Oct-2021 | 000 | 00000 |
| 0000 000000000 | 15-Sep-2021 | 000 | 00000 |
| 0000 00000000000 | 15-Sep-2021 | 000 | 00000 |
| 000000000 | 02-Sep-2021 | 0000000 000000 | 00000 |
| 00000000 000000000 | 01-Aug-2021 | 000000000000000000 | 00.00 |
| Omega Therapeutics | 30-Jul-2021 | IPO | 00000 |
| Nuvalent | 29-Jul-2021 | IPO | 00000 |
Logos Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialLogos Capital Team (4)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Virginia Yee | Chief Financial Officer & Chief Compliance Officer | San Francisco, CA | |||
| Ed Callaway | Chief Operating Officer | San Francisco, CA | |||
| Arsani William MD | Co-Founder, Managing Partner & Chief Investment Officer | 0 | 0 | 0 | San Francisco, CA |
| Graham Walmsley Ph.D | Co-Founder & General Partner | 0 | 0 | 0 | San Francisco, CA |
Logos Capital Co-Investors (276)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Janus Henderson Investors | 37 | 0 | 0 |
|
|
| RA Capital Management | 00 | 0 | 0 |
|
|
| Cormorant Asset Management | 00 | 0 | 0 |
|
|
| Citadel (Hedge Fund) | 00 | 0 | 0 |
|
|
| OrbiMed | 00 | 0 | 0 |
|
|